Asset
PACMILIMAB
CytomX Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03013491 | phase1_2 | terminated | 2017-01-19 | 2020-10-27 | CytomX Therapeutics | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas |
| NCT03993379 | phase2 | terminated | 2019-11-20 | 2020-05-21 | CytomX Therapeutics | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors |
| NCT04596150 | phase2 | completed | 2020-12-29 | 2023-06-02 | CytomX Therapeutics | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.